Allenberg J R, Schumacher H
Chirurgische Universitätsklinik Heidelberg.
Chirurg. 1995 Sep;66(9):870-7.
Animal experiments in the 80's demonstrated the feasibility of the concept first inaugurated by Dotter in 1969 of the endovascular implantation of a stent-graft prosthesis for the treatment of abdominal aortic aneurysm. In September 1990 Parodi was the first to treat a patient with an AAA using the implantation of a TPEG (transluminal placed endovascular stented graft). The rapid development of a variety of different devices can be observed since resulting in about 400 such prosthesis being implanted world wide for the treatment of AAA. The experience accumulated so far shows that severe complications can be avoided if morphology-based criteria are considered for the various treatment options (AAA classification type I, type IIa-c, type III). Despite considerable lethal incidents, technical mishaps and severe complications to date, the potential of TPEG for a structured approach to the treatment of AAA has to be evaluated. Prerequisites are 1) a competent team based on a close mutual cooperation of vascular surgeons and interventional radiologists, 2) a careful selection of patients, 3) TPEG to be performed in especially equipped operation theatres permitting the immediate application of conventional surgery if necessary, and 4) the implantation to be performed as a clinical study with flawless documentation of the procedure and follow-up.
20世纪80年代的动物实验证明了1969年由多特首次提出的血管内植入支架移植物假体治疗腹主动脉瘤这一概念的可行性。1990年9月,帕罗迪首次使用经皮腔内放置血管内带支架移植物(TPEG)治疗一名腹主动脉瘤患者。自那以后,可以观察到各种不同装置的迅速发展,导致全球约有400个此类假体被植入用于治疗腹主动脉瘤。迄今为止积累的经验表明,如果在各种治疗方案(腹主动脉瘤I型、IIa - c型、III型分类)中考虑基于形态学的标准,严重并发症是可以避免的。尽管迄今为止发生了相当多的致命事件、技术失误和严重并发症,但仍必须评估TPEG在结构化治疗腹主动脉瘤方法中的潜力。前提条件是:1)基于血管外科医生和介入放射科医生密切合作的专业团队;2)仔细挑选患者;3)TPEG要在特别配备的手术室进行,以便在必要时能立即进行传统手术;4)植入作为一项临床研究进行,对手术过程和随访进行完美记录。